SEED Therapeutics closes $30M Series A-3, FDA clears IND for lead RBM39 degrader

BeyondSpring Inc.

Second close of $6M completes $30M Series A-3; BeyondSpring to own ~38.03% on as-converted basis.
FDA cleared IND for ST-01156 (RBM39); first-in-human trial expected Q1 2026.
SEED has received ~$60M in equity and payments from Eli Lilly and Eisai partnerships.
BeyondSpring expects to continue consolidating SEED as it retains substantive control.

item 1.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.